Related Experiment Video
Updated: Jun 29, 2025
Production of Human CRISPR-Engineered CAR-T Cells
Published on: March 15, 2021
CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy
Hyeseon Park1, Yoo Kyung Kang2, Gayong Shim1
1School of Systems Biomedical Science and Integrative Institute of Basic Sciences, Soongsil University, Seoul 06978, Republic of Korea.
Abstract:
Clustered regularly interspaced short palindromic repeat-associated protein Cas9 (CRISPR/Cas9) technology is at the forefront of cancer immunotherapy innovation, offering precise and personalized treatment strategies. In this review, we discuss CRISPR/Cas9's ability to precisely edit the genome, its impact on immune checkpoint control, and its application in immune cell engineering, where it surpasses traditional gene editing techniques. Originally inspired by bacterial defense mechanisms, this technology has made great strides in cancer immunotherapy as a mechanism to specifically target the PD-1/PD-L1 pathway in immune checkpoint blockades. In addition, CRISPR/Cas9 plays an important role in cancer treatment by facilitating genetic modifications to enhance the properties of adoptive cell therapy, optimizing the therapeutic potential of this approach. This review provides an overview of the development of CRISPR/Cas9, its important role in immune checkpoint control, applications in immune cell engineering, and the current status of clinical trials. However, safety concerns related to off-target effects and unintended mutations require continued research and caution. Continued advances in CRISPR technology hold the promise of revolutionizing the cancer treatment paradigm, providing personalized and effective therapies for patients with various types of cancer.
Insights
Clustered regularly interspaced short palindromic repeat-associated protein Cas9 (CRISPR/Cas9) technology revolutionizes cancer immunotherapy by precisely editing genomes for targeted treatments. It enhances immune cell engineering and adoptive cell therapy, offering personalized cancer care.
Area of Science:
- Biotechnology
- Immunology
- Genetics
Background:
- CRISPR/Cas9 technology, derived from bacterial defense systems, offers precise genome editing capabilities.
- It has emerged as a powerful tool in cancer immunotherapy, surpassing traditional gene editing methods.
- CRISPR/Cas9 specifically targets the PD-1/PD-L1 pathway in immune checkpoint blockade strategies.
Purpose of the Study:
- To review the development and applications of CRISPR/Cas9 in cancer immunotherapy.
- To highlight CRISPR/Cas9's role in immune checkpoint control and immune cell engineering.
- To discuss the current clinical trial status and future potential of CRISPR/Cas9 in cancer treatment.
Main Methods:
- Genomic editing via CRISPR/Cas9.
- Immune cell engineering for adoptive cell therapy.
- Targeting of PD-1/PD-L1 pathway for immune checkpoint blockade.
Main Results:
- CRISPR/Cas9 enables precise genomic modifications for enhanced cancer immunotherapy.
- The technology optimizes adoptive cell therapy by improving immune cell properties.
- CRISPR/Cas9 shows significant promise in targeting immune checkpoints.
Conclusions:
- CRISPR/Cas9 technology is a transformative tool in cancer immunotherapy, offering personalized treatment strategies.
- Further research is needed to address safety concerns, including off-target effects and unintended mutations.
- Continued advancements in CRISPR technology hold the potential to revolutionize cancer treatment paradigms.
